Objectives: To compare the difference in characteristics of post-treatment prostate-specific antigen (PSA) kinetics among respective patients and their influence on disease prognosis. Methods: A cohort of totally 332 eligible patients with histologically confirmed and hormonally naïve prostate cancer, identified from the patients' database of Huashan Hospital, all received combined androgen deprivation therapy including bilateral orchiectomy or luteinizing hormone-releasing hormone antagonists with the oral administration of flutamide 250 mg t.i.d. All patients had their serum PSA level tested at least every 3 months in the first 2 years and at least once a half year from the third year on. PSA nadir, time to PSA nadir (TTPN), PSA normalization (<4 ng/ml), undetectable PSA level (<0.2 ng/ml), biochemical failure, overall survival and cancer-specific survival were analyzed. Results: PSA normalization, TTPN, and reaching the undetectable PSA level perhaps were the independent risk factors for predicting the three types of prognosis. Probably the best cut-off of PSA nadir was 0.2 ng/ml (sensitivity 65.7%, specificity 80.6%) and the best cut-off of TTPN was 10 months (sensitivity 71.6%, specificity 63.9%). Conclusions: These results implied that a lower level of PSA nadir and longer TTPN can predict a better disease prognosis.

Keywords:
Prostate cancer, Prostate-specific antigen, Androgen deprivation therapy, Prognosis
1.
Mottet N, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-583.
2.
Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596-1605.
3.
Choueiri TK, Xie W, D'Amico AV, et al: Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009;115:981-987.
4.
Park YH, Hwang IS, Jeong CW, et al: Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J Urol 2009;181:2520-2525.
5.
Huang SP, Bao BY, Wu MT, et al: Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 2011;71:1189-1197.
6.
Divrik RT, Turkeri L, Sahnin AF, et al: Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer. Urol Int 2012;88:25-33.
7.
Soloway MS, Hardeman SW, Hickey H, et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
8.
Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150(2 Pt 1): 379-385.
9.
Vicini FA, Vargas C, Abner A, et al: limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005;173:1456-1462.
10.
Hoffman RM: Clinical practice: screening for prostate cancer. N Engl J Med 2011;365:2013-2019.
11.
Heidenreich A, Aus G, Bolla M, et al: EAU guidelines on prostate cancer 2008. Eur Urol 2008;53:68-80.
12.
Peyromaure M, Debre B, Mao K, et al: Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol 2005;174:1794-1797.
13.
Ma CG, Ye DW, Li CL, et al: Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease. Zhonghua Wai Ke Za Zhi 2008;46:921-925.
14.
Noldus J, Graefen M, Huland E, et al: The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol 1998;159:2004-2007.
15.
Small EJ, McMillan A, Meyer M, et al: Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Urol 2001;19:1304-1311.
16.
Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF: Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000;163:1481-1485.
17.
Kantoff P: Recent progress in management of advanced prostate cancer. Oncology (Williston Park) 2005;19:631-636.
18.
Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
19.
Niu Y, Altuwaijri S, Lai KP, et al: Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008;105:12182-12187.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.